Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Sumitomo claims compounds for treating reperfusion injury

March 18, 1998

Cardiovascular disease gene discovered

March 17, 1998

Glaxo Wellcome, Boehringer Ingelheim collaborate to bring telmisartan to market

March 16, 1998

Yamanouchi investigates orally active AII antagonists

March 13, 1998

Vasopressin antagonists for treating CHF

March 12, 1998

Diovan HCT approved in U.S.

March 11, 1998

Inex finalizes acquisition of Lynx antisense assets

March 11, 1998

FDA advisory panel to review TMR using Heart Laser System

March 11, 1998

The effects of NPY antagonist BIBP-3226 on blood pressure and heart rate

March 11, 1998

UT-15 will move to phase III for pulmonary hypertension

March 10, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...